BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 17594194)

  • 1. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.
    Duvic M; Vu J
    Expert Opin Investig Drugs; 2007 Jul; 16(7):1111-20. PubMed ID: 17594194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vorinostat in cutaneous T-cell lymphoma.
    Duvic M; Vu J
    Drugs Today (Barc); 2007 Sep; 43(9):585-99. PubMed ID: 17940636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat.
    Duvic M; Vu J
    Biologics; 2007 Dec; 1(4):377-92. PubMed ID: 19707308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
    Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
    Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
    Olsen EA; Kim YH; Kuzel TM; Pacheco TR; Foss FM; Parker S; Frankel SR; Chen C; Ricker JL; Arduino JM; Duvic M
    J Clin Oncol; 2007 Jul; 25(21):3109-15. PubMed ID: 17577020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma.
    Kavanaugh SM; White LA; Kolesar JM
    Am J Health Syst Pharm; 2010 May; 67(10):793-7. PubMed ID: 20479100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
    Duvic M; Talpur R; Ni X; Zhang C; Hazarika P; Kelly C; Chiao JH; Reilly JF; Ricker JL; Richon VM; Frankel SR
    Blood; 2007 Jan; 109(1):31-9. PubMed ID: 16960145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
    Garcia-Manero G; Yang H; Bueso-Ramos C; Ferrajoli A; Cortes J; Wierda WG; Faderl S; Koller C; Morris G; Rosner G; Loboda A; Fantin VR; Randolph SS; Hardwick JS; Reilly JF; Chen C; Ricker JL; Secrist JP; Richon VM; Frankel SR; Kantarjian HM
    Blood; 2008 Feb; 111(3):1060-6. PubMed ID: 17962510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
    Duvic M; Dimopoulos M
    Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.
    Iwamoto M; Friedman EJ; Sandhu P; Agrawal NG; Rubin EH; Wagner JA
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):493-508. PubMed ID: 23820962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.
    Wada H; Tsuboi R; Kato Y; Sugaya M; Tobinai K; Hamada T; Shimamoto T; Noguchi K; Iwatsuki K
    J Dermatol; 2012 Oct; 39(10):823-8. PubMed ID: 22506596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
    Duvic M; Olsen EA; Breneman D; Pacheco TR; Parker S; Vonderheid EC; Abuav R; Ricker JL; Rizvi S; Chen C; Boileau K; Gunchenko A; Sanz-Rodriguez C; Geskin LJ
    Clin Lymphoma Myeloma; 2009 Dec; 9(6):412-6. PubMed ID: 19951879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.
    Mann BS; Johnson JR; He K; Sridhara R; Abraham S; Booth BP; Verbois L; Morse DE; Jee JM; Pope S; Harapanhalli RS; Dagher R; Farrell A; Justice R; Pazdur R
    Clin Cancer Res; 2007 Apr; 13(8):2318-22. PubMed ID: 17438089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
    Cyrenne BM; Lewis JM; Weed JG; Carlson KR; Mirza FN; Foss FM; Girardi M
    Blood; 2017 Nov; 130(19):2073-2083. PubMed ID: 28972015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET/CT for the evaluation of response to therapy of cutaneous T-cell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial.
    Kuo PH; Carlson KR; Christensen I; Girardi M; Heald PW
    Mol Imaging Biol; 2008; 10(6):306-14. PubMed ID: 18665425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.
    Dummer R; Beyer M; Hymes K; Epping MT; Bernards R; Steinhoff M; Sterry W; Kerl H; Heath K; Ahern JD; Hardwick JS; Garcia-Vargas J; Baumann K; Rizvi S; Frankel SR; Whittaker SJ; Assaf C
    Leuk Lymphoma; 2012 Aug; 53(8):1501-8. PubMed ID: 22239668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
    Tiffon C; Adams J; van der Fits L; Wen S; Townsend P; Ganesan A; Hodges E; Vermeer M; Packham G
    Br J Pharmacol; 2011 Apr; 162(7):1590-602. PubMed ID: 21198545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
    Hymes KB
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):98-109. PubMed ID: 20371442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vorinostat (Zolinza) for cutaneous T-Cell lymphoma.
    Med Lett Drugs Ther; 2007 Mar; 49(1256):23-4. PubMed ID: 17351559
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.